Aleia Crim, MD
Gynecologic Oncology · Oklahoma City, OKNPI 1861789315
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $654 of the $862 with a category attached, or 75.9%. It is spread thinly across 13 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $330 and has fallen 60.0% since, to $132 in 2024. That places this record below the midpoint for gynecologic oncology clinicians in OK, where the typical reported total is $3,072.
Across 41 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clovis Oncology, Inc.$154
- AstraZeneca$132
- Eisai Inc.$125
- Merck$100
- Amgen$75
- Intuitive Surgical$72
- plus $204 from 7 others
What the payments were for
- Food & beverage$65476%
- Education$20824%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clovis Oncology, Inc. | 10 | $154 |
| AstraZeneca | 4 | $132 |
| Eisai Inc. | 6 | $125 |
| Merck | 5 | $100 |
| Amgen | 4 | $75 |
| Intuitive Surgical | 1 | $72 |
| AMAG Pharmaceuticals, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $37 |
| GSK | 2 | $31 |
| Fortovia Therapeutics, Inc. | 2 | $29 |
| AbbVie | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Tesaro, Inc. | 1 | $21 |
How this compares
$862 in reported general payments places this provider in the 25th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $11,048 |
| Ondansetron Hcl | 14 | $470 |
| Letrozole | 16 | $412 |
| Dexamethasone | 13 | $365 |
| Prochlorperazine Maleate | 20 | $361 |
| Duloxetine Hcl | 12 | $211 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $116 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Oklahoma City
- Debra RichardsonOklahoma City$97K
- Camille JacksonOklahoma City$35K
- Tara CastellanoOklahoma City$26K
- Joan WalkerOklahoma City$11K
- Christina WashingtonOklahoma City$9K
- Elizabeth EvansOklahoma City$3K
- Lauren DockeryOklahoma City$3K
- Ana ValenteOklahoma City$2K
- Nicole MinaltOklahoma City$2K
- Jacqueline BohnOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.